| name | es-male-cpp-hormone-test |
| description | This skill determines whether serum testosterone (preferably via LC-MS/MS) and luteinizing hormone levels should be obtained before 10:00 AM to support clinical evaluation of male childhood cancer survivors suspected of or at risk for central precocious puberty after gonadotoxic exposure. It is triggered by clinician questions such as "Should I check testosterone and LH for this boy at risk for early puberty after chemo?" or "Is morning hormone testing needed for CPP evaluation in males with gonadotoxic history?" |
Order testosterone and LH for male CPP evaluation
STEP 1 — Gather Information
Collect patient demographics (male, age), cancer treatment history focusing on gonadotoxic exposures (alkylating agents, testicular radiotherapy), clinical signs suggestive of CPP (testicular volume >4 mL, pubic hair Tanner stage ≥2, penile growth, accelerated growth velocity, behavioral changes), and timing of sample (prefer before 10:00 AM). Document any prior hormone results.
STEP 2 — Rule In / Rule Out
Is the patient a male childhood cancer survivor with a history of gonadotoxic exposure and either suspected CPP based on clinical findings or considered at risk for developing CPP? If yes, proceed to Step 3; if no, do not order testosterone and LH at this time and reassess during routine follow‑up.
STEP 3 — Classify or Stratify
Classify the indication as either "suspected CPP" (clear clinical signs of early puberty) or "at risk" (gonadotoxic exposure without definitive pubertal changes). Both classifications indicate the need for biochemical testing to complement the clinical assessment. Proceed to Step 4 to order the labs.
STEP 4 — Decide
Order a morning serum testosterone sample (preferably measured by liquid chromatography–tandem mass spectrometry, LC‑MS/MS) and a luteinizing hormone (LH) level, ensuring the blood draw occurs before 10:00 AM.
Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on testicular volume for pubertal staging in males with gonadotoxic injury, as it may reflect germ‑cell damage rather than Leydig‑cell activation. Interpret LH elevations in the context of possible primary gonadal injury; elevated LH does not automatically confirm central puberty. Avoid using immunoassays prone to interference; LC‑MS/MS is preferred for testosterone. Ensure the sample is drawn before 10:00 AM due to diurnal variation; fasting is not required.
Concrete Clinical Example
A 9‑year‑old boy treated for acute lymphoblastic leukemia with testicular radiotherapy presents with Tanner stage 2 pubic hair and testicular volume of 5 mL. The clinician asks, “Should I check testosterone and LH for this boy at risk for early puberty after chemo?” History confirms male survivor, gonadotoxic exposure, and suspected CPP. Serum testosterone (LC‑MS/MS) and LH are drawn at 09:00 AM; results show testosterone 0.8 ng/mL and LH 1.2 IU/L, supporting early central activation and prompting consideration of GnRH agonist therapy.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, DOI:10.1210/jc.2018-01175
